TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$1.49B
• Dividend Yield: N/A
• Average Volume (3M): 103.96K
• Price to Earnings (P/E): 36.8
• Beta (1Y): 0.53
• Revenue Growth: 38.48%
• EPS Growth: N/A
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 74,840
• 30 Day Avg. Volume: 103,960
• PEG Ratio: 0.13
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -32.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.40
• Price Target Upside: 24.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: HK$2.00 ▲(3.63%Upside)

The overall stock score is driven by strong financial performance and a solid balance sheet, offset by liquidity concerns and limited cash flow. Technical analysis indicates mixed signals, with short-term bullish trends but potential bearish momentum. Valuation concerns due to a high P/E ratio further weigh on the score.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

TOT BIOPHARM generates revenue primarily through the sale of its oncology drugs and therapies. The company invests in the development of both proprietary biologics and biosimilars, which are critical in the treatment of cancer. Revenue streams include direct sales to healthcare providers and distributors, as well as potential licensing agreements and partnerships with other pharmaceutical companies for co-development and commercialization. Additionally, the company might receive government grants or subsidies that support its research and development efforts. Key factors contributing to its earnings include its robust pipeline of drug candidates, strategic collaborations, and its ability to bring cost-effective treatments to market.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

The company has shown significant improvement in revenue, profitability, and operational efficiency, with positive EBIT and EBITDA margins. The balance sheet is strong with low Debt-to-Equity Ratio and positive Return on Equity. However, liquidity remains a concern due to negative Free Cash Flow.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.10B	780.63M	442.18M	76.33M	22.49M
Gross Profit	782.43M	573.99M	370.62M	27.47M	15.53M
EBITDA	84.96M	10.45M	-5.41M	-224.51M	-254.71M
Net Income	34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet
Total Assets	1.51B	1.43B	1.26B	710.26M	641.18M
Cash, Cash Equivalents and Short-Term Investments	381.26M	358.36M	458.05M	152.81M	225.53M
Total Debt	395.47M	345.65M	289.53M	208.56M	7.41M
Total Liabilities	779.12M	739.41M	546.59M	375.17M	58.83M
Stockholders Equity	729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow
Free Cash Flow	-7.17M	-146.77M	-180.19M	-290.45M	-285.30M
Operating Cash Flow	116.40M	56.43M	59.93M	-175.14M	-263.12M
Investing Cash Flow	-122.50M	-164.10M	-282.76M	-108.39M	12.53M
Financing Cash Flow	34.18M	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Positive. The current price of 1.93 is above the 20-day moving average (MA) of 1.90, above the 50-day MA of 1.90, and above the 200-day MA of 1.87, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 50.24 is Neutral, neither overbought nor oversold. The STOCH value of 52.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	65 Neutral	HK$1.49B	36.75	4.92%	―	38.48%	―
6622	55 Neutral	HK$1.46B	―	-12.04%	―	260.78%	40.04%
Sector *	52 Neutral	$7.53B	0.20	-63.81%	2.31%	16.15%	0.40%
2181	42 Neutral	HK$2.00B	―	-86.56%	―	190.48%	40.11%
6978	37 Underperform	HK$1.85B	―	-228.99%	―	―	44.88%
2511	36 Underperform	HK$2.01B	―	-67.57%	―	―	54.79%
2185	32 Underperform	HK$1.57B	―	-12.49%	―	―	50.94%

TOT BIOPHARM International Co. Ltd. Corporate Events

TOT BIOPHARM Updates Nomination Committee Terms to Enhance Governance

TOT BIOPHARM International Co. Ltd. has announced the approval and implementation of new Terms of Reference for its Nomination Committee, effective July 1, 2025. The committee is tasked with reviewing the board’s structure, identifying qualified director candidates, and ensuring board diversity and independence. This move is expected to enhance the company’s governance and align its board composition with its strategic goals, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Passes Key Resolutions at AGM

TOT BIOPHARM International Co. Ltd. successfully passed all proposed resolutions at its Annual General Meeting held on June 20, 2025. These resolutions included the approval of financial statements, re-election of directors, and granting of mandates for share allotment and buyback, indicating strong shareholder support and strategic alignment for future corporate governance and operational strategies.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Announces 2025 AGM Details and Key Resolutions

TOT BIOPHARM International Co. Ltd. has announced the details of its upcoming annual general meeting, scheduled for June 20, 2025. The meeting will address several key resolutions, including the approval of the company’s financial statements for 2024, the re-election of board members, and the reappointment of PricewaterhouseCoopers as auditors. Additionally, the meeting will consider authorizing the board to manage the company’s share capital, which could impact the company’s financial strategy and shareholder value.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Proposes Name Change to BioDlink International

TOT BIOPHARM International Co. Ltd. has announced a proposal to change its English name to BioDlink International Company Limited, subject to shareholder and regulatory approval. This name change is intended to better align with the company’s business strategy and enhance its corporate image, without affecting current shareholders’ rights or the company’s operations.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

TOT BIOPHARM Reports Revenue Growth Amidst Profitability Challenges in Q1 2025

TOT BIOPHARM International Co. Ltd. reported a 13% year-on-year increase in revenue for the first quarter of 2025, reaching RMB252,200 thousand. This growth is primarily due to the steady increase in sales of its self-developed products. Despite the revenue growth, the company’s net income decreased compared to the same period last year, highlighting potential challenges in maintaining profitability. Stakeholders are advised to exercise caution as the company’s financial results have shown fluctuations in the past and may continue to do so.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.0000 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.